Simultaneous determination of mosapride and its active des-p-fluorobenzyl and 4′-N-oxide metabolites in rat plasma using UPLC-MS/MS: An application for a pharmacokinetic study

被引:16
作者
Zhao, Longshan [1 ]
Sun, Xiaohong [1 ]
Xiong, Zhili [1 ]
Wang, Shaojie [2 ]
机构
[1] Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Minist Educ, Key Lab Struct Based Drugs Design & Discovery, Shenyang 110016, Peoples R China
关键词
Mosapride; Metabolite; UPLC-ESI-MS/MS; Pharmacokinetics; ORAL ADMINISTRATIONS; N-OXIDE; CITRATE; SINGLE; IDENTIFICATION; MONKEYS; DOGS;
D O I
10.1016/j.talanta.2015.01.021
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
An efficient and sensitive ultra-performance chromatography-tandem mass spectrometry method to simultaneously determinate and quantify mosapride (M) and its des-p-fluorobenzyl (M1) and 4'-N-oxide (M2) metabolites using carbamazepine as the internal standard (IS) in rat plasma has been developed and validated. Analytes were extracted from aliquots of plasma with ethyl acetate after alkalization using saturated sodium carbonate solution. The chromatographic separation was conducted on a BEH C-18 column (100 mm x 2.1 mm, 1.7 mu m) with the gradient elution using a mobile phase of acetonitrile - 0.2% formic acid in water at a flow rate of 0.25 mL/min for 4 min. The tandem mass spectrometric detection was conducted using multiple reaction monitoring (MRM) by the positive electrospray ionization (ESI). The ion transitions monitored were raiz 422 -> 198 for mosapride, raiz 314 -> 198 for M1, miz 438 -> 109 for M2 and miz 237 -> 194 for IS. The linear ranges of the calibration curves were 1.0-2000 ng/mL for M, 0.75-1875 ng/mL for M1 and 0.4-40 ng/mL for M2. And the corresponding lower limits of quantitation (LLOQ) of the method were 1.0, 0.75, 0.4 ng/mL for M, M1 and M2, respectively. The intra- and inter-day precision for all analytes were less than 8.1% and 11.6%, respectively. The inter-assay mean accuracy was between -6.4% and 8.1%. No relevant cross-talk and matrix effect were observed. There were significant differences between male and female rats for M, M1 and M2. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:130 / 135
页数:6
相关论文
共 19 条
[1]  
[Anonymous], 2001, Guidance for industry, bioanalytical method validation
[2]  
Aoki K, 2013, ENDOCR J, V60, P493
[3]   Liquid chromatography-tandem mass spectrometric method for determination of mosapride citrate in equine tissues [J].
Aoki, Yoichi ;
Hakamata, Hideki ;
Igarashi, Yu ;
Uchida, Kazunari ;
Kobayashi, Hisato ;
Hirayama, Norio ;
Kotani, Akira ;
Kusu, Fumiyo .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 858 (1-2) :135-142
[4]  
Huang J, 2011, ARZNEIMITTELFORSCH, V61, P167, DOI 10.1055/s-0031-1296184
[5]   Effects of the Oral Administration of Mosapride Citrate on Capsule Endoscopy Completion Rate [J].
Ida, Yosuke ;
Hosoe, Naoki ;
Imaeda, Hiroyuki ;
Bessho, Rieko ;
Ichikawa, Riko ;
Naganuma, Makoto ;
Kanai, Takanori ;
Hibi, Toshifumi ;
Ogata, Haruhiko .
GUT AND LIVER, 2012, 6 (03) :339-343
[6]   Effect of Mosapride Citrate on Gastric Emptying in Interferon-Induced Gastroparesis [J].
Kawamura, Etsushi ;
Enomoto, Masaru ;
Kotani, Kohei ;
Hagihara, Atsushi ;
Fujii, Hideki ;
Kobayashi, Sawako ;
Iwai, Shuji ;
Morikawa, Hiroyasu ;
Kawabe, Joji ;
Tominaga, Kazunari ;
Tamori, Akihiro ;
Shiomi, Susumu ;
Kawada, Norifumi .
DIGESTIVE DISEASES AND SCIENCES, 2012, 57 (06) :1510-1516
[7]   Pharmacokinetic and bioavailability studies using 5 mg mosapride tablets in healthy Korean volunteers [J].
Kim, Shin-Hee ;
Park, Yoo-Sin ;
Kim, Jung Mogg ;
Park, Hae-Jeong ;
Lee, Min-Ho ;
Park, Hoon-Ki ;
Kim, Young-Jae ;
Cho, Sam Hyun ;
Shaw, Leslie M. ;
Kang, Ju-Seop .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2012, 50 (07) :524-531
[8]   DECOMPOSITION OF CLOZAPINE N-OXIDE IN THE QUALITATIVE AND QUANTITATIVE-ANALYSIS OF CLOZAPINE AND ITS METABOLITES [J].
LIN, G ;
MCKAY, G ;
HUBBARD, JW ;
MIDHA, KK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1994, 83 (10) :1412-1417
[9]  
MATSUMOTO S, 1993, ARZNEIMITTEL-FORSCH, V43-2, P1095
[10]  
Nushiroda T., 2000, DRUG METAB DISPOS, V28, P1231